Full Text View
Tabular View
No Study Results Posted
Related Studies
Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression
This study has been completed.
Study NCT00083954   Information provided by AstraZeneca

First Received on June 3, 2004.   Last Updated on January 3, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Bipolar Disorder
Additional conditions recognized in this trial
Depression
Depressive Disorder
More general conditions related to this trial
Affective Disorders, Psychotic
Behavioral Symptoms
Mental Disorders
Mood Disorders
Interventions listed in this trial
Quetiapine Fumarate
Additional drug interventions recognized in this trial
Quetiapine
More general drug interventions related to this trial
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
AstraZeneca


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services